Synergistic effects of sorafenib and cilostazol in HepG2 cells
Bibliographic Information
Authors: Effat H.; Mohamed O.A.; Sharaky M.; Heikal S.; Elshahawy S.; Ayad E.G.
Journal: Journal of Biosciences
Publisher: Springer
Publication Date: 2026-07-16
Volume: 51 | Issue: 3
Article No.: 35
ISSN: 2505991
DOI: 10.1007/s12038-026-00607-w
Scopus: View article on Scopus
Document Type: Article
Authors and Affiliations
Abstract
Sorafenib, an established multi-kinase inhibitor, is a cornerstone of treatment for advanced hepatocellular carcinoma (HCC). This study explores the efficacy of combining sorafenib with cilostazol, a phosphodiesterase-3 inhibitor with emerging anticancer properties, using the HepG2 cell line. We assessed the effects on cell proliferation, apoptosis, and the expression levels of key regulatory proteins and genes, including VEGF, SMAD4, Bcl-2, TGF-β, Bax, and caspase-3. The combination treatment resulted in a significant reduction in the IC50 of sorafenib. Colony formation assays demonstrated that both cilostazol and sorafenib individually inhibited HepG2 cell growth, with combination therapy leading to a further decrease in colony numbers compared to individual treatments. Enhanced apoptosis was observed with the combination, as evidenced by increased Bax and caspase-3 levels and decreased Bcl-2 expression. Additionally, the combination therapy exhibited potent anti-angiogenic effects, significantly reducing VEGF and TGF-β levels. These findings suggest a synergistic interaction between sorafenib and cilostazol, offering promising insights for optimizing therapeutic strategies in HCC management. © The Author(s), under exclusive licence to Indian Academy of Sciences 2026.
Keywords
Angiogenesis; apoptosis; cilostazol; combination therapy; hepatocellular carcinoma; sorafenib; caspase 3; protein Bax; protein bcl 2; Smad4 protein; transforming growth factor beta; vasculotropin; bioassay; cell; disease treatment; gene expression; inhibitor; management; optimization; antiangiogenic activity; antineoplastic activity; Article; cancer chemotherapy; cell growth; cell proliferation; colony formation; comparative study; controlled study; drug efficacy; Hep-G2 cell line; human; IC50; liver cell carcinoma; protein expression; synergistic effect
Citation Information
Scopus Citations: 0
For comprehensive information about the Theodor Bilharz Research Institute (TBRI) , its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments , as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit